



Experiences of People Who Use Different Long-Acting Injectables For HIV Prevention

EACS 2025; October 15-18, 2025; Paris, France

Poster MeP20.4.LB

Presenting author: Kimberley Brown; kimberley.x.brown@viivhealthcare.com

How does HIV affect the body?

Human immunodeficiency virus (HIV) makes copies of itself throughout the body and kills the CD4 cells that fight off infections

How can HIV be prevented?

A person who may be exposed to HIV can take pre-exposure prophylaxis (also known as PrEP), a medicine that stops the virus from making copies of itself inside the body, thereby greatly reducing the chance of acquiring HIV

What PrEP medicine was studied here?

- This study compared two different long-acting injectable PrEP medicines, cabotegravir (CAB), taken as 1 injection and lenacapavir (LEN), taken as 2 injections
- Understanding people's experiences with different long-acting PrEP options is important

What was the purpose of this study?

This study compared people's experiences with local reactions such as swelling, bumps, pain, or redness that can happen at the spot where an injection is given on the body (known as injection site reactions) with CAB injections versus LEN injections

People received each of the treatments in sequence and completed questionnaires about their experiences 7 days after injection. Healthcare providers checked for any reactions at the site of injection up to 21 days after injection.



CAB (1 dose, injection into the muscle)

Half of the people received CAB first, then LEN



LEN (1 dose, injections under the skin)

Half of the people received LEN first, then CAB

Who is included in this study?

63 adults who did not have HIV aged ≥ 18 years in the United States joined the study

- 61 people received a CAB injection and 62 people received LEN injections
- 61 people completed questionnaires about their experience with CAB and 60 people completed questionnaires about their experience with LEN



29%
were Black or African American



38%
were Hispanic or Latine



33%
were female

Which long-acting PrEP option was more acceptable?




After receiving a dose of CAB or LEN:


How acceptable was/were your local reactions?

How acceptable was your pain associated with your local reactions?

More people reported that local reactions with CAB injections were totally or very acceptable compared with LEN



(42 out of 61 people) reported **CAB** was “totally or very acceptable”



(29 out of 60 people) reported **LEN** was “totally or very acceptable”

Which long-acting PrEP option was preferred?

After receiving doses of both CAB and LEN, most people reported that they preferred CAB



After receiving both CAB and LEN:
which medication do you prefer?

90%
preferred
CAB
(54/60 people)



10%
preferred
LEN
(6/60 people)

Reasons for preferring CAB

Of the 54 people who preferred CAB:

- 40** said less pain during injection administration
- 33** said less pain or soreness after injection administration
- 31** said how long the injection nodules or swelling last
- 30** said the size of the injection nodules or swelling
- 29** said the number of injections received at each visit

Reasons for preferring LEN

Of the 6 people who preferred LEN:

- 5** said less pain or soreness after injection administration
- 3** said how long the injection nodules or swelling last
- 3** said the size of the injection nodules or swelling
- 3** said fewer number of side effects
- 2** said less severe side effects

How many people experienced local reactions while receiving CAB compared with LEN?

People reported more severe pain with LEN compared with CAB on Day 1 of injection, though people reported similar pain with CAB and LEN after that



had a **local reaction** other than pain when receiving **CAB**



had a **local reaction** other than pain when receiving **LEN**

What does this mean for people who are thinking about using long-acting PrEP?

- After receiving doses of both CAB and LEN, more people found that CAB injections were acceptable compared with LEN injections and most people reported that they preferred CAB
- More people experienced local reactions other than pain with LEN injections compared with CAB injections



Poster presentation title:

Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals

Authors:

Justine Boles,¹ Emilie Elliot,² Dainielle Fox,³ Apinya Vutikullird,⁴ Amber Mottola,⁴ Kim Fletcher,⁵ Kehui Wang,⁶ Suryakant Somvanshi,⁷ Richard Grove,⁵ Katie Strano,⁸ Katherine L. Nelson,³ Laure Dupont-Benjamin,⁹ V. Paul DiMondi,³ Jean van Wyk,¹ Harmony P. Garges,⁶ Kimberley Brown³

¹ViiV Healthcare, London, UK; ²ViiV Healthcare, Madrid, Spain; ³ViiV Healthcare, Durham, NC, USA; ⁴Ark Clinical Research, Long Beach, CA, USA; ⁵GSK, London, UK; ⁶GSK, Durham, NC, USA; ⁷GSK, GCC, Bengaluru, India; ⁸IQVIA, Kansas City, MO, USA; ⁹ViiV Healthcare, Rueil-Malmaison, France

Disclaimer

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.